[BiO BB] Re: Help with an Executive Summit focused on
Eric_Cervera at frost.com
Mon Sep 23 12:24:51 EDT 2002
Public Relations Specialist
Executive Summits Division. . . Where Business Does Business!
Frost & Sullivan
Office # 210-247-2446
Fax # 210-348-1003
As a Growth Consulting organization, we enable our clients to meet their
Growth Objectives by maximizing the results from their Growth Portfolio
and identifying new Growth Opportunities..
----- Forwarded by Eric Cervera/Mountain_View_CA/US/Frost & Sullivan on
09/23/02 11:27 AM -----
"J.W. Bizzaro" <jeff at bioinformatics.org>
Sent by: jeff at dexter.geoserve.net
09/23/02 11:26 AM
To: Eric Cervera <ecervera at frost.com>
Subject: Re: Help with an Executive Summit focused on
You're welcome to send your message to our Bulletin Board:
bbb at bioinformatics.org
Eric Cervera wrote:
> My name is Eric Cervera. I am the Public Relation
> Specialist with Frost & Sullivan. I understand you are the
> Newsletter and Website Content Editor for the
> Bioinformatics.org. I was wondering I you could lend me a
> hand on project I am working on. I am responsible for
> evaluating and recruiting speaker and what we call Thought
> Leader for our Executive Summits. I have and Executive
> Summit coming up focused on Maximizing Outcomes of
> Information Technology in Drug Discovery and Development
> for which I am currently seeking nominations for the
> position of Thought Leader .
> I was wondering if you would not mind sending the message
> to you e-newsletter subscriber database. Below is the copy
> for the message I am asking you to send. This is not a
> sales call. There are no fees associated with being a
> Thought Leader. The Thought Leader position is a
> prestigious and important role. We will be recognizing
> these Thought Leaders for the knowledge and experience.
> Please see the text below and let me know if this is doable.
> I am currently accepting nominations for the prestigious
> role of Thought Leader at our high-caliber Executive Summit
> focused on: Maximizing Outcomes of Information Technology
> in Drug Discovery and Development.
> There are no presentations or speeches required. All I ask
> it the Though Leader share his/her insight and perspective
> in one of the topics listed below.
> Concurrent Thinktanks, November 5, 2002
> __Thinktank 1: InSilico Drug Discovery
> __Thinktank 2: Genomics
> __Thinktank 3: Proteomics
> Concurrent Roundtables, November 6, 2002
> __ Roundtable 1: Managing Focused Libraries
> __ Roundtable 2: E-Clinical Integration
> __ Roundtable 3: Personalized Medicine
> As a Thought Leader there are a number of exclusive
> privileges you will enjoy:
> Full Complimentary Thought Leader Pass for the Executive
> Forum and General Session (Sunday-Wednesday $2095 value)
> Your name, title and company in our program brochure and in
> our program materials as a participating Thought Leader
> Sunday's Executive Golf Tournament on us - we've got the
> green fees!
> Complimentary daily continental breakfast, lunch and
> scheduled receptions and dinners
> and more!
> The following is a list of confirmed Thought Leaders:
> Francois Nader, MD, MBA, Senior Vice President Medical
> Affairs, North America, Aventis Pharmaceutical
> Kris Arora, PhD,Vice President, GRA Information Management,
> Sheryl Torr-Brown, PhD, Worldwide Head of Knowledge
> Management and Scientific Development, Pfizer
> Sangtae Kim, PhD, Vice President and Information Officer,
> Lilly Research Laboratories
> Mark Cockett, PhD, Executive Director, Applied Genomics,
> Bristol-Myers Squibb Company
> Charles Jaffe, MD, Ph.D, Director of Medical Informatics,
> AstraZeneca Pharmaceuticals
> Abdel Laoui, Head Chemoinformatics, Lead Generation
> Informatics, Aventis
> Nigel Beeley, PhD, Vice President and Chief Chemical
> Officer- Arena Pharmaceuticals
> Daniel Marshak, PhD, VP and Chief Technology Officer-
> Joe Guiles, PhD, Director of High Throughput Chemistry,
> Aventis Pharmaceuticals Inc.
> Alan Wilson, PhD, Senior Director and Senior Fellow,
> PreClinical Development, Pharmacia
> Nathan Siemers, Associate Director of Bioinformatics,
> Bristol-Myers Squibb Company
> Bob Ladner, Sr. VP & Chief Science Officer, Dyax
> Steven Gold, PhD, Director of Bioinformatics, CuraGen
> Thomas Rea, VP Bio-Pharmaceutical Development, Esperion
> Richard Labaurdiniere, PhD, Senior Vice President Research
> and Development, Genome Therapeutics
> Robert Davis, Executive VP of Drug Discovery, ACADIA
> Lloyd Segal, President & CEO - Caprion Pharmaceuticals
> Jurgen Bajorath Ph.D, Senior Director, Computer Aided Drug
> Discovery, Albany Molecular Research
> Jim Rizzi, Director of Computational Technology- Array
> Bruce Keyt, PhD, Vice President Preclinical Development,
> Abgenix Inc.
> Robin Jackman, VP of Corporate Development, Sequenom
> Terrence Chew, MD, SVP, Clinical and Regulatory, Peregrine
> David O'Reilly, VP of Corporate Development, Iconix
> Sheila DeWitt, PhD, Vice President Drug Discovery, ArQule
> John Saunders, PhD, Vice President of Chemistry, Neucrine
> Biosciences, Inc.
> There are a few ground rules:
> 1. You must be a Director or above.
> 2. You must be from a Pharmaceutical or Biotechnology or
> Biopharma company with sales in excess of $10 million/
> 4. Each nominee must go through a brief screening process.
> 5. Rules subject to change
> For more information about this event go to
> Please call me at 210-355-4806 or email me at
> ecervera at frost.com to nominate yourself or a colleague.
> Eric Cervera
> Public Relations Specialist
> Executive Summits Division
> Frost & Sullivan
> Office # 210-247-2446
> Fax # 210-348-1003
J.W. Bizzaro jeff at bioinformatics.org
Director, Bioinformatics.Org http://bioinformatics.org/~jeff
"As we enjoy great advantages from the inventions of others, we
should be glad of an opportunity to serve others by any invention
of ours; and this we should do freely and generously."
-- Benjamin Franklin
Frost & Sullivan
This email, its content and any files transmitted with it are intended
solely for the addressee(s) and may be
legally privileged and/or confidential. If you are not the intended
recipient please delete and contact the
sender by return.
Messages sent via this medium may be subject to delays, non-delivery and
unauthorized alteration. This
email has been prepared using information believed by the author to be
reliable and accurate, but Frost &
Sullivan makes no warranty as to accuracy or completeness. In particular,
Frost & Sullivan does not
accept responsibility for changes made to this email after it was sent.
Any opinions or recommendations
expressed herein are solely those of the author. They may be subject to
change without notice.
-------------- next part --------------
An HTML attachment was scrubbed...
More information about the BBB